NASDAQ : EWTX
Edgewise Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 38.9 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 4.22B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 47.62M | 40.02M | 31.87M | 23.45M | 17.63M | 11.03M |
| Research & Development | 171.27M | 151.39M | 126.97M | 90.91M | 54.03M | 32.19M |
| Operating Expenses | 218.90M | 191.41M | 158.83M | 114.36M | 71.66M | 43.22M |
| Operating Income | -218.90M | -191.41M | -158.83M | -114.36M | -71.66M | -43.22M |
| Interest & Investment Income | 21.67M | 23.61M | 25.02M | 14.19M | 4.02M | 402.00K |
| Pretax Income | -197.22M | -167.79M | -133.81M | -100.16M | -67.64M | -42.81M |
| Net Income | -197.22M | -167.79M | -133.81M | -100.16M | -67.64M | -42.81M |
| Net Income to Common | -197.22M | -167.79M | -133.81M | -100.16M | -67.64M | -42.81M |
| Shares Outstanding (Basic) | 106.60M | 102.93M | 92.41M | 63.72M | 53.59M | 37.53M |
| Shares Outstanding (Diluted) | 106.60M | 102.93M | 92.41M | 63.72M | 53.59M | 37.53M |
| EPS (Basic) | -1.85 | -1.63 | -1.45 | -1.57 | -1.26 | -1.14 |
| EPS (Diluted) | -1.85 | -1.63 | -1.45 | -1.57 | -1.26 | -1.14 |
| Free Cash Flow | -158.83M | -144.07M | -110.34M | -97.69M | -58.18M | -34.17M |
| Free Cash Flow Per Share | -1.49 | -1.40 | -1.19 | -1.53 | -1.09 | -0.91 |
| EBITDA | -216.77M | -189.32M | -156.76M | -112.81M | -71.29M | -42.94M |
| D&A For EBITDA | 2.13M | 2.08M | 2.07M | 1.55M | 368.00K | 272.00K |
| EBIT | -218.90M | -191.41M | -158.83M | -114.36M | -71.66M | -43.22M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 72.32M | 61.15M | 41.67M | 86.10M | 21.99M | 15.57M |
| Short-Term Investments | 388.39M | 468.96M | 428.50M | 232.30M | 329.95M | 265.22M |
| Cash & Short-Term Investments | 460.71M | 530.11M | 470.17M | 318.39M | 351.95M | 280.79M |
| Prepaid Expenses | 6.45M | 13.28M | 5.31M | 8.60M | 5.05M | 2.98M |
| Total Current Assets | 471.52M | 543.38M | 475.48M | 327.00M | 357.00M | 283.77M |
| Property, Plant & Equipment | 8.17M | 9.22M | 11.07M | 12.69M | 9.85M | 912.00K |
| Long-Term Deferred Charges | 262.00K | 300.00K | 251.00K | |||
| Other Long-Term Assets | 48.00K | 548.00K | ||||
| Total Assets | 479.69M | 552.60M | 486.82M | 340.04M | 367.10M | 285.23M |
| Accounts Payable | 4.67M | 6.01M | 5.58M | 4.03M | 6.11M | 3.84M |
| Accrued Expenses | 13.77M | 20.35M | 17.29M | 11.77M | 9.87M | 6.68M |
| Current Portion of Leases | 1.02M | 1.01M | 996.00K | 980.00K | 608.00K | |
| Other Current Liabilities | 9.59M | |||||
| Total Current Liabilities | 29.04M | 27.37M | 23.86M | 16.77M | 16.59M | 10.52M |
| Long-Term Leases | 2.57M | 2.98M | 3.74M | 4.43M | 3.80M | |
| Other Long-Term Liabilities | 329.00K | |||||
| Total Liabilities | 31.61M | 30.35M | 27.60M | 21.20M | 20.39M | 10.85M |
| Common Stock | 10.00K | 10.00K | 9.00K | 7.00K | 6.00K | 5.00K |
| Additional Paid-In Capital | 1.10B | 1.07B | 837.36M | 563.49M | 492.67M | 351.85M |
| Retained Earnings | -652.71M | -546.37M | -378.58M | -244.76M | -144.60M | -76.96M |
| Comprehensive Income & Other | -500.00K | 677.00K | 420.00K | 99.00K | -1.35M | -514.00K |
| Total Common Equity | 448.08M | 522.26M | 459.22M | 318.83M | 346.72M | 274.38M |
| Shareholders' Equity | 448.08M | 522.26M | 459.22M | 318.83M | 346.72M | 274.38M |
| Total Liabilities & Equity | 479.69M | 552.60M | 486.82M | 340.04M | 367.10M | 285.23M |
| Total Debt | 3.59M | 3.99M | 4.74M | 5.41M | 4.41M | |
| Net Cash (Debt) | 457.12M | 526.12M | 465.43M | 312.98M | 347.54M | 280.79M |
| Net Cash Per Share | 4.29 | 5.11 | 5.04 | 4.91 | 6.48 | 7.48 |
| Filing Date Shares Outstanding | 108.60M | 107.27M | 95.21M | 93.11M | 63.26M | 49.51M |
| Total Common Shares Outstanding | 107.78M | 106.25M | 94.84M | 70.45M | 63.26M | 49.50M |
| Working Capital | 442.48M | 516.01M | 451.62M | 310.23M | 340.41M | 273.25M |
| Book Value Per Share | 4.16 | 4.92 | 4.84 | 4.53 | 5.48 | 5.54 |
| Tangible Book Value | 448.08M | 522.26M | 459.22M | 318.83M | 346.72M | 274.38M |
| Tangible Book Value Per Share | 4.16 | 4.92 | 4.84 | 4.53 | 5.48 | 5.54 |
| Machinery | 4.92M | 4.88M | 4.54M | 4.25M | 2.26M | 1.61M |
| Construction In Progress | 77.00K | 80.00K | 7.34M | |||
| Leasehold Improvements | 9.81M | 9.65M | 9.65M | 8.73M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -197.22M | -167.79M | -133.81M | -100.16M | -67.64M | -42.81M |
| Depreciation & Amortization | 2.33M | 2.27M | 2.29M | 1.73M | 538.00K | 272.00K |
| Loss (Gain) From Sale of Investments | -5.36M | -7.67M | -12.54M | -9.52M | -543.00K | |
| Stock-Based Compensation | 36.04M | 34.75M | 24.71M | 17.56M | 10.92M | 4.40M |
| Change in Accounts Payable | -208.00K | 272.00K | 1.74M | -92.00K | 47.00K | 2.65M |
| Change in Other Net Operating Assets | 6.04M | -5.65M | 8.59M | -1.47M | 4.04M | 1.98M |
| Operating Cash Flow | -158.38M | -143.82M | -109.03M | -91.95M | -52.63M | -33.51M |
| Capital Expenditures | -454.00K | -256.00K | -1.31M | -5.75M | -5.55M | -668.00K |
| Investment in Securities | 166.85M | -32.53M | -183.34M | 108.63M | -65.03M | -241.56M |
| Investing Cash Flow | 166.40M | -32.79M | -184.66M | 102.89M | -70.58M | -242.23M |
| Issuance of Common Stock | 20.89M | 196.09M | 249.51M | 53.33M | 129.89M | 186.51M |
| Other Financing Activities | -262.00K | -165.00K | -251.00K | -124.00K | ||
| Financing Cash Flow | 20.89M | 196.09M | 249.25M | 53.17M | 129.64M | 186.38M |
| Net Cash Flow | 28.91M | 19.48M | -44.43M | 64.10M | 6.43M | -89.35M |
| Free Cash Flow | -158.83M | -144.07M | -110.34M | -97.69M | -58.18M | -34.17M |
| Free Cash Flow Per Share | -1.49 | -1.40 | -1.19 | -1.53 | -1.09 | -0.91 |
| Levered Free Cash Flow | -92.31M | -87.34M | -63.22M | -61.66M | -35.48M | -19.26M |
| Unlevered Free Cash Flow | -92.31M | -87.34M | -63.22M | -61.66M | -35.48M | -19.26M |
| Change in Working Capital | 5.83M | -5.37M | 10.33M | -1.56M | 4.09M | 4.63M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 4.22B | 2.63B | 2.53B | 694.27M | 565.13M | 753.24M |
| Enterprise Value | 3.77B | 2.07B | 2.04B | 410.10M | 202.97M | 462.76M |
| Last Close Price | 38.90 | 24.82 | 26.70 | 10.94 | 8.94 | 15.28 |
| PB Ratio | 9.36 | 5.03 | 5.50 | 2.18 | 1.63 | 2.75 |
| P/TBV Ratio | 9.43 | 5.03 | 5.50 | 2.18 | 1.63 | 2.75 |
| Debt / Equity Ratio | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | |
| Net Debt / Equity Ratio | -1.02 | -1.01 | -1.01 | -0.98 | -1.00 | -1.02 |
| Net Debt / EBITDA Ratio | 2.11 | 2.78 | 2.97 | 2.77 | 4.88 | 6.54 |
| Net Debt / FCF Ratio | 2.88 | 3.65 | 4.22 | 3.20 | 5.97 | 8.22 |
| Quick Ratio | 15.86 | 19.37 | 19.70 | 18.98 | 21.22 | 26.69 |
| Current Ratio | 16.24 | 19.85 | 19.93 | 19.50 | 21.52 | 26.97 |
| Return on Equity (ROE) | -38.03% | -34.19% | -34.40% | -30.10% | -21.78% | -21.34% |
| Return on Assets (ROA) | -25.03% | -23.02% | -24.01% | -20.21% | -13.73% | -12.97% |
| Return on Capital Employed (ROCE) | -48.60% | -36.40% | -34.30% | -35.40% | -20.40% | -15.70% |
| Earnings Yield | -4.76% | -6.39% | -5.29% | -14.43% | -11.97% | -5.68% |
| FCF Yield | -3.76% | -5.48% | -4.36% | -14.07% | -10.29% | -4.54% |
| Buyback Yield / Dilution | -9.70% | -11.38% | -45.02% | -18.90% | -42.82% | -4,977.96% |